Evidence map›Paper›PMID 26617867›Full record

ArticleInternational journal of clinical and experimental pathology2015

Prognostic significance of HOXD13 expression in human breast cancer.

Zhen-Bin Zhong, Ming Shan, Cheng Qian, Tong Liu, Qing-Yu Shi, Ji Wang, Yan Liu, Yang Liu, Yuan-Xi Huang, Da Pang

Open access · greenAbstract read
In one paragraph

Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Zhen-Bin ZhongDepartment of Breast Surgery, The Affiliated Tumor Hospital of Harbin Medical University Harbin, China.
Ming ShanDepartment of Breast Surgery, The Affiliated Tumor Hospital of Harbin Medical University Harbin, China.
Cheng QianDepartment of Breast Surgery, The Affiliated Tumor Hospital of Harbin Medical University Harbin, China.
Tong LiuDepartment of Breast Surgery, The Affiliated Tumor Hospital of Harbin Medical University Harbin, China.
Qing-Yu ShiDepartment of Breast Surgery, The Affiliated Tumor Hospital of Harbin Medical University Harbin, China.
Ji WangDepartment of Breast Surgery, The Affiliated Tumor Hospital of Harbin Medical University Harbin, China.
Yan LiuDepartment of Biostatistics, School of Public Health, Harbin Medical University Harbin, China.
Yang LiuDepartment of Breast Surgery, The Affiliated Tumor Hospital of Harbin Medical University Harbin, China.
Yuan-Xi HuangDepartment of Breast Surgery, The Affiliated Tumor Hospital of Harbin Medical University Harbin, China.
Da PangDepartment of Breast Surgery, The Affiliated Tumor Hospital of Harbin Medical University Harbin, China ; Heilongjiang Academy of Medical Sciences Heilongjiang, China.
Harbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Homeobox protein Hox-D13 has been recognized as a tumor suppressor in pancreatic cancer. To evaluate the function of HOXD13 in invasive breast cancer pathogenesis, we examined HOXD13 expression in 434 breast cancer tissues and 230 their counterpart normal breast tissues by immunohistochemistry using a tissue microarray (TMA). The association between HOXD13 expression and clinicopathological factors was analyzed by use of Chi-square test. Kaplan-Meier survival curves and log-rank tests were applied to analyze the survival status. Cox regression was applied for multivariate analysis of prognosis. We found that low HOXD13 expression accounts for 84.3% in breast cancer tissues. Low HOXD13 expression was significantly associated with large tumor size (P=0.038) and positive lymph node metastasis (LNM) (P=0.026). In Kaplan-Meier survival curves and log-rank tests, the patients with HOXD13-negative breast cancer showed significantly poorer outcomes (69.867 ± 1.058 months) in terms of overall survival (OS) than positive-HOXD13-expression patients (76.248 ± 1.069 months) (P=0.003). And in multivariate analysis, low level of HOXD13 expression was a significant unfavorable prognostic factor. So we conclude that down-regulation of HOXD13 might be a potentially useful prognostic marker for patients with breast cancer.

Indexed as

AdultAgedBiomarkers, TumorBreast NeoplasmsCarcinoma, Ductal, BreastFemaleHomeodomain ProteinsHumansImmunohistochemistryKaplan-Meier EstimateMiddle AgedPrognosisProportional Hazards ModelsTissue Array AnalysisTranscription FactorsBiomarkers, TumorHomeodomain ProteinsHOXD13 protein, humanTranscription Factorsbreast cancerHOXD13prognosistissue microarray

Identifiers

PMID26617867
PMCPMC4637683
OpenAlexW2409199313

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.